SCHEMBL12269802

SCHEMBL12269802

CN(C1C=CCCC1)S(=O)(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.58
KDM4E B2RXH2 1/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
HTR2A P28223 5/20 0.50
HTR2C P28335 4/20 0.50
SIGMAR1 Q99720 1/20 0.50
GAA P10253 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HSD11B1 P28845 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
LMNA P02545 1/20 0.38
ACHE P22303 1/20 0.37
USP2 O75604 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CCR5 P51681 1/20 0.37
HTR1A P08908 1/20 0.37
DRD2 P14416 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18615282 0.82 ESR1 (0.48) ALDH1A1KDM4EMEN1KMT2AHTR2A
SCHEMBL12077352 0.76 ALDH1A1 (0.93) ALDH1A1KDM4EMEN1KMT2AHTR2A
SCHEMBL2505847 0.74 ALDH1A1 (0.83) ALDH1A1KDM4EMEN1KMT2AHTR2A
SCHEMBL14145779 0.74 HTR2A (0.41) ALDH1A1MEN1KMT2AHTR2AHTR2C
SCHEMBL4159760 0.73 ALDH1A1 (1.00) ALDH1A1KDM4EMEN1KMT2AHTR2A
SCHEMBL7572053 0.73 PKM (0.34) ALDH1A1KDM4EMEN1KMT2AAPOBEC3G
SCHEMBL24157929 0.71 ESR1 (0.40) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL2316644 0.70 MAPT (0.44) ALDH1A1KDM4EMEN1KMT2AHTR2A
SCHEMBL12077315 0.69 KMT2A (0.59) ALDH1A1KDM4EMEN1KMT2AHTR2A
SCHEMBL23126460 0.69 ALDH1A1 (0.33) ALDH1A1APOBEC3GHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895781-B2 Transition metal-catalyzed C—H amination using unactivated amines GEORGETOWN UNIVERSITY (US) 2014-11-25 US disclosed
US-8895781-B2 Transition metal-catalyzed C—H amination using unactivated amines GEORGETOWN UNIVERSITY (US) 2014-11-25 US disclosed
US-20110213146-A1 Transition Metal-Catalyzed C-H Amination Using Unactivated Amines GEORGETOWN UNIVERSITY (US) 2011-09-01 US disclosed
WO-2010028159-A2 TRANSITION METAL-CATALYZED C-H AMINATION USING UNACTIVATED AMINES GEORGETOWN UNIVERSITY (US) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213146-A1 Transition Metal-Catalyzed C-H Amination Using Unactivated Amines AOC3, AOC2, MPO ALDH1A1 2510/4885KDM4E 2335/4885MEN1 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.